Denali Therapeutics (DNLI) Payables (2017 - 2026)

Denali Therapeutics (DNLI) has reported Payables for 10 consecutive years, with $40.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 377.42% year-over-year to $40.4 million; the TTM figure through Mar 2026 stood at $40.4 million (up 377.42% YoY), while the FY2025 annual figure was $505000.0, down 95.47% from the prior year.
• Payables climbed to $40.4 million in Q1 2026 per DNLI's latest filing, from $505000.0 in the prior quarter.
• Across five years, Payables topped out at $40.4 million in Q1 2026 and bottomed at $505000.0 in Q4 2025.
• Historically, Payables has averaged $10.0 million across 5 years, with a median of $8.5 million in 2023.
• Annual changes were most pronounced in 2025 — Payables sank 95.47% — and 2026, when it jumped 377.42%.
• Denali Therapeutics' Payables stood at $2.8 million in 2022, then surged by 239.89% to $9.5 million in 2023, then increased by 17.44% to $11.1 million in 2024, then tumbled by 95.47% to $505000.0 in 2025, then soared by 7896.04% to $40.4 million in 2026.
• Business Quant data shows DNLI's Payables at $40.4 million in Q1 2026, $505000.0 in Q4 2025, and $6.7 million in Q3 2025.